COVAX is one of three pillars of the Access to COVID-19 Tools (ACT) Accelerator, which was launched in April 2020 in response to the COVID-19 pandemic.  Image credit: Unsplash | Source: gavi.org

The ACT Accelerator brings together governments, global health organisations, manufacturers, scientists, private sector, civil society and philanthropy, with the aim of providing innovative and equitable access to COVID-19 diagnostics, treatments and vaccines. Image credit: Unsplash | Source: gavi.org

COVAX aims to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world. Image credit: Unsplash | Source: WHO

COVAX is co-led by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organisation (WHO). Image credit: Unsplash

By joining COVAX, self-financing countries are guaranteed sufficient doses to protect a certain proportion of their population, depending upon how much they buy into it. Image credit: ANI | Source: gavi.org

On the other hand, funded countries will receive enough doses to vaccinate up to 20 per cent of their population in the longer term.  This is subject to funding availability, Image credit: Unsplash | Source: gavi.org

COVAX Advance Market Commitment (AMC) is to support the participation of 92 lower-middle and low-income economies in the COVAX facility ensuring these countries get equal access to vaccines. Image credit: iStock | Source: gavi.org

COVAX's initital goal is to procure and deliver 2 billion doses of vaccines by the end of 2021.

Image credit: Unsplash

COVID vaccination

COVAX offers:

- Diverse and actively managed portfolio of vaccines Image credit: Unsplash | Source: gavi.org

COVAX offers:

- End the acute phase of the pandemic

Image credit: Unsplash